<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01824368</url>
  </required_header>
  <id_info>
    <org_study_id>FEC-TH</org_study_id>
    <secondary_id>2012-000633-39</secondary_id>
    <nct_id>NCT01824368</nct_id>
  </id_info>
  <brief_title>Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.</brief_title>
  <acronym>FEC-TH</acronym>
  <official_title>FOTOAFERESIS EXTRACORPÓREA EN EL TRASPLANTE HEPÁTICO. ENSAYO CLINICO EN FASE II DE SEGURIDAD Y EFICACIA EN PACIENTES CON RETIRADA PROGRESIVA DE LA INMUNOSUPRESIÓN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Service, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of extracorporeal photopheresis in&#xD;
      patients with long-standing liver transplantation subjected to a progressive reduction of&#xD;
      immunosuppression by complications arising from its use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse event rate and rate of transplant rejection</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>People with liver transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal Photopheresis Procedure (FEC)</intervention_name>
    <description>The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.&#xD;
1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.&#xD;
Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex.</description>
    <arm_group_label>People with liver transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been receiving liver transplant two years ago.&#xD;
&#xD;
          -  Be 18 years or older.&#xD;
&#xD;
          -  Treatment with immunosuppression including cyclosporine or tacrolimus.&#xD;
&#xD;
          -  Having a normal liver function in the last year&#xD;
&#xD;
          -  Not have suffered acute rejection in the last year and have no chronic rejection&#xD;
&#xD;
          -  Submit any significant side effects from medication immunosuppressive (hypertension,&#xD;
             creatinine greater than 1.7 mgDl, diabetes, morbid obesity, osteoporosis,&#xD;
             hyperlipidemia, severe hirsutism, neurotoxicity novo malignancy, etc.)&#xD;
&#xD;
          -  Etiology of underlying disease: alcoholic cirrhosis with or without hepatocarcinoma,&#xD;
             metabolic diseases, amyloidotic polyneuropathy family, biliary atresia, fulminant&#xD;
             hepatitis non-A, non-B, non-C, cirrhosis cryptogenic and generally causes no viral or&#xD;
             autoimmune.&#xD;
&#xD;
          -  Patients offering sufficient guarantees of adherence to protocol&#xD;
&#xD;
          -  Patients who give written informed consent for participate in the study.&#xD;
&#xD;
          -  It is necessary that the patient meets all inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying disease of the autoimmune (primary sclerosing cholangitis, autoimmune&#xD;
             cirrhosis, primary biliary cirrhosis) or epatocarcinoma about cirrhosis of viral or&#xD;
             autoimmune.&#xD;
&#xD;
          -  Patients with chronic rejection, or acute rejection in the last year.&#xD;
&#xD;
          -  Patients with liver retransplantation.&#xD;
&#xD;
          -  patients with history of hypersensitivity or idiosyncratic reactions to methoxsalen,&#xD;
             psoralen the compounds or any of the excipients.&#xD;
&#xD;
          -  patients with melanoma, cutaneous basal cell carcinoma or squamous cell coexistent.&#xD;
&#xD;
          -  Patients with aphakia.&#xD;
&#xD;
          -  Patients taking Oxoralen.&#xD;
&#xD;
          -  Pregnant women or nursing mothers, or adults of childbearing age not using effective&#xD;
             contraception.&#xD;
&#xD;
          -  Participation in another clinical trial.&#xD;
&#xD;
          -  Inability to understand informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.red-tercel.com</url>
    <description>Red de Terapia Celular (TerCel)</description>
  </link>
  <link>
    <url>http://www.ffis.es</url>
    <description>Fundación para la Formación e Investigación Sanitarias Región de Murcia</description>
  </link>
  <link>
    <url>http://www.murciasalud.es</url>
    <description>Servicio Murciano de Salud</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 1, 2013</study_first_submitted>
  <study_first_submitted_qc>April 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

